Latest News

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

Senate HELP Committee hearing reveals how 340B drug program expansion reflects hospital business strategy rather than patient benefit.

Congressional Budget Office confirms 340B program expansion driven by hospital exploitation rather than pharmaceutical price inflation.

HRSA clarifies 340B eligibility for STI clinics while manufacturers challenge Ryan White program participation.

HRSA's 340B pilot program replicates existing successful models rather than addressing structural program exploitation.

340B program expansion drains billions from state Medicaid budgets while failing to deliver promised drug cost savings.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

Pugh reflects on 340B policy and patient advocacy in ensuring equitable medication access.

Nashville Fireside Chat: state funding cuts, 340B reform, and HIV criminalization law changes.

S.4395 would divert Ryan White resources from PLWHA to PrEP, threatening the safety net for vulnerable populations.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.

Examines how 340B program expansion correlates with declining hospital charity care for vulnerable patients.

Explores accountability mechanisms in the 340B program and oversight requirements for patient protection.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Overview of the 340B Drug Discount Program for patient advocates covering program history and key policy issues.

Calls for restoring Obama-era guidance defining 340B patient protections and enforcement mechanisms.